Tests tocilizumab with clot removal for a type of ischemic stroke
Tests tocilizumab alongside endovascular treatment in adults with acute posterior circulation stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Key facts
- Where
- Anyang, Beijing, Guankou, Hebi, Heyuan, Huaibei, Jiaxing, Linyi, Lishui, Luoyang, Maoming, Nanyang, Puyang, Qinhuangdao, Shangqiu, Suzhou, Taizhou, Tangshan, Wenzhou, Xiangyang, Xianyang, Xinxiang, Yancheng, Yueqing, Yuncheng, Zhoukou, and Zibo, ChinaSee the 30 sites
- Phase
- Phase 3
Where in China
- Anyang People's HospitalAnyang, ChinaTaking people
- Capital Medical Univercity Xuanwu HospitalBeijing, ChinaTaking people
- Liuyang Jili HospitalGuankou, ChinaTaking people
- Junxian People's HospitalHebi, ChinaTaking people
- Heyuan People's HospitalHeyuan, ChinaTaking people
- Suixi County HospitalHuaibei, ChinaTaking people
- Jiaxing First People's HospitalJiaxing, ChinaTaking people
- People's Hospital of LinyiLinyi, ChinaTaking people
- Lishui Central HospitalLishui, ChinaTaking people
- Luoyang Central HospitalLuoyang, ChinaTaking people
- Huazhou People's HospitalMaoming, ChinaTaking people
- Nanyang Central HospitalNanyang, ChinaTaking people
- Puyang Oiled General HospitalPuyang, ChinaTaking people
- Qinhuangdao Second People's HospitalQinhuangdao, ChinaTaking people
- Ningling County HospitalShangqiu, ChinaTaking people
- Shangqiu First People's HospitalShangqiu, ChinaTaking people
- Suzhou Municipal HospitalSuzhou, ChinaTaking people
- Taizhou enze HospitalTaizhou, ChinaTaking people
- Tangshan Gongren HospitalTangshan, ChinaTaking people
- Yutian County HospitalTangshan, ChinaTaking people
- Wenzhou People's HospitalWenzhou, ChinaTaking people
- Xiangyang First People's HospitalXiangyang, ChinaNot yet recruiting
- Xianyang First People's HospitalXianyang, ChinaTaking people
- The First Affiliated Hospital of Henan Medical UniversityXinxiang, ChinaTaking people
- Yancheng First People's HospitalYancheng, ChinaTaking people
- People's Hospital of YueqingYueqing, ChinaTaking people
- Yuncheng Central HospitalYuncheng, ChinaTaking people
- People's Hospital of XihuaZhoukou, ChinaTaking people
- Shenqiu County HospitalZhoukou, ChinaTaking people
- Zibo Central hospitalZibo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Capital Medical University
- Trial code
- NCT07509645
- Record updated
- 3 November 2026
- Original description
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.Read full original descriptionShow less
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Inclusion: Age 18 years or older, of either sex; Acute ischemic stroke caused by occlusion of the basilar artery; Decide to undergo emergency endovascular treatment; Time from stroke onset to groin puncture within 24 hours; National Institutes of Health Stroke Scale (NIHSS) ≥ 10; Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6; Signed informed consent from the patients or the legally authorized representatives.
Exclusion: Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days; Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study; Any circumstance that, as assessed by the investigators, might result in harm to the patients if study therapy is initiated; Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage; Pre-stroke modified Rankin scale (mRS) score >1; Known allergy to tocilizumab or excipients; Known allergy to iodinated contrast agents; History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases; Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia; Presence of autoimmune diseases or use of immunosuppressive drugs; Systemic infectious diseases; Other conditions that the investigator considers might affect compliance or preclude participation in this study; Neutrophils < 2 × 10\^9 /L; Platelets < 100 × 10\^9 /L; Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL); Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2 times the upper limit of normal; Known recent or current serum creatinine >2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) <60 mL/min; Anticipated difficulty in completing endovascular treatment due to vascular tortuosity; Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite blood pressure control; Pregnant, lactating, or planning pregnancy within 90 days.